Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies

le Tibes, Raoul, Mesa, Ruben A
Foilsithe 2014

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia

le Tibes, Raoul, Bogenberger, James M.
Foilsithe in Front Oncol (2019)

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

le Bogenberger, James M., Delman, Devora, Hansen, Nanna, Valdez, Riccardo, Fauble, Veena, Mesa, Ruben A., Tibes, Raoul
Foilsithe in Leuk Lymphoma (2014)

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation

le Tibes, Raoul, Kornblau, Steven M., Qiu, Yihua, Mousses, Spyro M., Robbins, Christiane, Moses, Tracy, Carpten, John D.
Foilsithe 2007

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

le Weiss, Glen J., Tibes, Raoul, Blaydorn, Lisa, Jameson, Gayle, Downhour, Molly, White, Erica, Caro, Ivor, Von Hoff, Daniel D.
Foilsithe 2011

Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma

le Mahadevan, Daruka, Northfelt, Donald W., Chalasani, Pavani, Rensvold, Diane, Kurtin, Sandra, Von Hoff, Daniel D., Borad, Mitesh J., Tibes, Raoul
Foilsithe in Int J Clin Oncol (2012)

Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit

le Padrnos, Leslie, Bennett, Robert, Kosiorek, Heidi, Dueck, Amylou C., Northfelt, Donald, Mikhael, Joseph, Tibes, Raoul, Khera, Nandita, Mesa, Ruben A.
Foilsithe in J Cancer Educ (2018)

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma

le Arora, Shilpi, Gonzales, Irma M, Hagelstrom, R Tanner, Beaudry, Christian, Choudhary, Ashish, Sima, Chao, Tibes, Raoul, Mousses, Spyro, Azorsa, David O
Foilsithe 2010

Functional proteomic profiling of AML predicts response and survival

le Kornblau, Steven M., Tibes, Raoul, Qiu, Yi Hua, Chen, Wenjing, Kantarjian, Hagop M., Andreeff, Michael, Coombes, Kevin R., Mills, Gordon B.
Foilsithe 2009

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study

le Tibes, Raoul, Borad, Mitesh J., Dutcus, Corina E., Reyderman, Larisa, Feit, Kevie, Eisen, Andrew, Verbel, David A., Von Hoff, Daniel D.
Foilsithe in Br J Cancer (2018)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib

le Thacker, Curtis A, Weiss, Glen J, Tibes, Raoul, Blaydorn, Lisa, Downhour, Molly, White, Erica, Baldwin, Jason, Hoff, Daniel D, Korn, Ronald L
Foilsithe 2012

Triazolo[4,5-d]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells

le Lough, Lea, Sherman, Dan, Becerra-Flores, Manuel, Vasudevan, Deepika, Lavinda, Olga, Ni, Eric, Wang, Hong, Ryoo, Hyung Don, Tibes, Raoul, Cardozo, Timothy
Foilsithe in Comput Struct Biotechnol J (2018)

Corrigendum to “Triazolo[4,5-d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells” [Comput. Struct. Biotec...

le Lough, Lea, Sherman, Dan, Becerra-Flores, Manuel, Vasudevan, Deepika, Lavinda, Olga, Ni, Eric, Wang, Hong, Ryoo, Hyung Don, Tibes, Raoul, Cardozo, Timothy
Foilsithe in Comput Struct Biotechnol J (2020)

Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma

le Tiedemann, Rochelle L., Hlady, Ryan A., Hanavan, Paul D., Lake, Douglas F., Tibes, Raoul, Lee, Jeong-Heon, Choi, Jeong-Hyeon, Ho, Thai H., Robertson, Keith D.
Foilsithe in Oncotarget (2015)

The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials

le Borad, Mitesh J., Curtis, Kelly K., Babiker, Hani M., Benjamin, Martin, Tibes, Raoul, Ramanathan, Ramesh K., Wright, Karen, Dueck, Amylou C., Jameson, Gayle, Von Hoff, Daniel D.
Foilsithe 2012

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

le Tibes, Raoul, Al-Kali, Aref, Oliver, Gavin R, Delman, Devora H, Hansen, Nanna, Bhagavatula, Keerthi, Mohan, Jayaram, Rakhshan, Fariborz, Wood, Thomas, Foran, James M., Mesa, Ruben A., Bogenberger, James M.
Foilsithe in J Hematol Oncol (2015)

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

le Mughal, Tariq I., Vannucchi, Alessandro M., Soverini, Simona, Bazeos, Alexandra, Tibes, Raoul, Saglio, Giuseppe, Abdel-Wahab, Omar, Pardanani, Animesh, Hehlmann, Rudiger, Barbui, Tiziano, Van Etten, Richard, Tefferi, Ayalew, Goldman, John M.
Foilsithe 2014

Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment

le Chen, Xufeng, Glytsou, Christina, Zhou, Hua, Narang, Sonali, Reyna, Denis E., Lopez, Andrea, Sakellaropoulos, Theodore, Gong, Yixiao, Kloetgen, Andreas, Yap, Yoon Sing, Wang, Eric, Gavathiotis, Evripidis, Tsirigos, Aristotelis, Tibes, Raoul, Aifantis, Iannis
Foilsithe in Cancer Discov (2019)

Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

le Lorza, Andres M. Arias, Ravi, Harshan, Philip, Rohit C., Galons, Jean-Philippe, Trouard, Theodore P., Parra, Nestor A., Von Hoff, Daniel D., Read, William L., Tibes, Raoul, Korn, Ronald L., Raghunand, Natarajan
Foilsithe in Sci Rep (2020)

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

le Ravandi, Farhad, Gojo, Ivana, Patnaik, Mrinal M., Minden, Mark D., Kantarjian, Hagop, Johnson-Levonas, Amy O., Fancourt, Craig, Lam, Raymond, Jones, Mary Beth, Knox, Clayton D., Rose, Shelonitda, Patel, Payal Shah, Tibes, Raoul
Foilsithe in Leuk Res (2016)